Get started
Author

Dale M. Watt

Observed names: Dale M Watt, Dale Watt, Watt, Dale M.
ORCID: 0000-0002-0443-176X
Observed ORCID: 0000-0002-0443-176X
OpenAlex ID: A5000424441
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity
2021 · Colin Hutton, Felix Heider, et al. · Cancer Cell · 347
PDF
Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes
2025 · Declan Whyte, Sophie L Fisher, et al. · EMBO Reports · 15
KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2024 · Sigrid K. Fey, Arafath K. Najumudeen, et al. · Cancer Research · 12
PDF
Heterogeneity in Pancreatic Cancer Fibroblasts—TGFβ as a Master Regulator?
2021 · Dale M. Watt, Jennifer P. Morton · Cancers · 12
PDF
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis
2025 · Celine I. Wittke, Eric C. Cheung, et al. · JHEP Reports · 8
PDF
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma
2025 · Lindsay C. Spender, Dale M. Watt, et al. · British Journal of Cancer · 5
PDF
Modeling human tumor evolution in mice
2026 · Dale M. Watt, Louise E. Mitchell, et al. · STAR Protocols · 1
Cholesterol and p53 promote senescence and systemic fibrosis in metabolic dysfunction-associated steatohepatitis
2026 · Celine I Wittke, Dale M Watt, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Supplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2026 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2026 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2026 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2026 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2026 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2026 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
PDF
Figure 2 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
PDF
Supplementary Figure 5 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Data from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Figure 1 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Figure 3 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Supplementary Figure 4 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
PDF
Supplementary Figure 6 from KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition
2025 · Sigrid K. Fey, Arafath K. Najumudeen, et al.
Works count: 27
Citation count: 400
H-index: 5
I10-index: 4
Year
Topic
Type